Table 1 Demographic and clinical data of the PCa patients and cancer-free controls included in the training and validation sets
Characteristics | Prostate cancer | Control | ||||||
|---|---|---|---|---|---|---|---|---|
Training set VOCs | External set VOCs | Training set VCCs | External set VCCs | Training set VOCs | External set VOCs | Training set VCCs | External set VCCs | |
Number of subjects | 40 | 18 | 40 | 18 | 42 | 18 | 40 | 18 |
Mean Age ± SD (years) | 64.4 ± 6.4 | 61.8 ± 5.2 | 63.7 ± 6.5 | 63.4 ± 5.3 | 59.3 ± 3.0 | 59.6 ± 2.62 | 59.3 ± 2.8 | 59.8 ± 2.7 |
PSA (ng/mL), n (%) | ||||||||
<4 | 3 (7.5%) | 1 (5.6%) | – | 4 (22.2%) | – | – | – | – |
4–10 | 24 (60%) | 13 (72.2%) | 28 (70%) | 9 (50%) | – | – | – | – |
>10 | 13 (32.5%) | 4 (22.2%) | 12 (30%) | 5 (27.8%) | – | – | – | – |
Gleason score, n (%) | ||||||||
≤6 | 6 (15%) | 3 (16.7%) | 8 (20%) | 1 (5.6%) | – | – | – | – |
=7 | 25 (62.5%) | 12 (66.7%) | 24 (60%) | 13 (72.2%) | – | – | – | – |
≥8 | 9 (22.5%) | 3 (16.7%) | 8 (20%) | 4 (22.2%) | – | – | – | – |
Clinical stage, n (%) | ||||||||
I | 3 (7.5%) | 3 (16.7%) | 4 (10%) | 2 (11.1%) | – | – | – | – |
II | – | 2 (11.1%) | 2 (4%) | – | – | – | – | – |
IIA | 7 (17.5%) | 4 (22.2%) | 9 (22.5%) | 2 (11.1%) | – | – | – | – |
IIB | 15 (37.5%) | 2 (11.1%) | 11 (27.5%) | 6 (33.3%) | – | – | – | – |
III | 13 (32.5%) | 5 (27.8%) | 10 (25%) | 8 (44.4%) | – | – | – | – |
IV | 2 (5%) | 2 (11.1%) | 4 (10%) | – | – | – | – | – |
Alcoholism, n (%) | 7 (17.5%) | 4 (22.2%) | 9 (22.5%) | 2 (11.1%) | 3 (7.1%) | – | 2 (5%) | 1 (5.6%) |
Smoking, n (%) | 2 (5%) | – | 2 (5%) | – | 5 (11.9%) | 2 (11.1%) | 6 (15%) | 1 (5.6%) |
Obesity, n (%) | 6 (15%) | 4 (22.2%) | 7 (17.5%) | 3 (16.7%) | 7 (16.7%) | 3 (16.7%) | 7 (17.5%) | 2 (11.1%) |
Cardiac condition, n (%) | 5 (12.5%) | 6 (33.3%) | 7 (17.5%) | 4 (22.2%) | – | 1 (5.6%) | – | 1 (5.6%) |
AH, n (%) | 21 (52.5%) | 8 (44.4%) | 19 (47.5%) | 10 (55.6%) | 14 (33.3%) | 9 (50%) | 20 (50%) | 3 (16.7%) |
Dyslipidemia, n (%) | 16 (40%) | 8 (44.4%) | 14 (35%) | 10 (55.6%) | 16 (38.1%) | 9 (50%) | 16 (40%) | 8 (44.4%) |
Diabetes, n (%) | 9 (22.5%) | 3 (16.7%) | 8 (20%) | 4 (22.2%) | 6 (14.3%) | 1 (5.6%) | 5 (12.5%) | 1 (5.6%) |
HTG, n (%) | 2 (5%) | – | 1 (2.5%) | 1 (5.6%) | 1 (2.4%) | – | – | 1 (5.6%) |
HC, n (%) | 3 (7.5%) | – | 1 (2.5%) | 2 (11.1%) | 4 (9.5%) | 1 (5.6%) | 3 (7.5%) | 2 (11.1%) |
BPH, n (%) | – | – | – | – | 13 (31%) | 4 (22.2%) | 11 (27.5%) | 4 (22.2%) |
Prostatitis, n (%) | – | – | – | – | 1 (2.4%) | 1 (5.6%) | 2 (5%) | – |
